Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Baxter
McKinsey
Harvard Business School
Citi
Colorcon
Accenture
Healthtrust
Express Scripts
Moodys

Generated: October 18, 2017

DrugPatentWatch Database Preview

Akorn Company Profile

« Back to Dashboard

What is the competitive landscape for AKORN, and what generic alternatives to AKORN drugs are available?

AKORN has one hundred and sixty approved drugs.

There is one US patent protecting AKORN drugs. There are three tentative approvals on AKORN drugs.

There are two patent family members on AKORN drugs in two countries and one hundred and thirty-two supplementary protection certificates in twelve countries.

Summary for Applicant: Akorn

International Patents:2
US Patents:1
Tradenames:127
Ingredients:116
NDAs:160
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Akorn
ETHOSUXIMIDE
ethosuximide
CAPSULE;ORAL040686-001May 28, 2008ABRXNoNo► Subscribe► Subscribe► Subscribe
Akorn Inc
PHENYLEPHRINE HYDROCHLORIDE
phenylephrine hydrochloride
SOLUTION/DROPS;OPHTHALMIC207926-001Jan 15, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Akorn
SODIUM NITROPRUSSIDE
sodium nitroprusside
INJECTABLE;INJECTION208635-001May 4, 2017APRXNoNo► Subscribe► Subscribe► Subscribe
Akorn Mfg
INNOVAR
droperidol; fentanyl citrate
INJECTABLE;INJECTION016049-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Akorn
ETHAMBUTOL HYDROCHLORIDE
ethambutol hydrochloride
TABLET;ORAL075095-001Nov 30, 1999ABRXNoNo► Subscribe► Subscribe► Subscribe
Akorn
HEPARIN SODIUM
heparin sodium
INJECTABLE;INJECTION017486-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Akorn Inc
CYCLOPENTOLATE HYDROCHLORIDE
cyclopentolate hydrochloride
SOLUTION/DROPS;OPHTHALMIC205937-001Dec 9, 2015ATRXNoNo► Subscribe► Subscribe► Subscribe
Akorn
IC-GREEN
indocyanine green
INJECTABLE;INJECTION011525-004Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Akorn Inc
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER
clindamycin phosphate
INJECTABLE;INJECTION203048-002Apr 4, 2013APRXNoNo► Subscribe► Subscribe► Subscribe
Akorn
HYDROCORTISONE ACETATE
hydrocortisone acetate
INJECTABLE;INJECTION009637-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Akorn

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Akorn
SUFENTA PRESERVATIVE FREE
sufentanil citrate
INJECTABLE;INJECTION019050-001May 4, 1984► Subscribe► Subscribe
Akorn
ALFENTA
alfentanil hydrochloride
INJECTABLE;INJECTION019353-001Dec 29, 1986► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Akorn Drugs

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2008014036► Subscribe
European Patent Office2043601► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Akorn Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016000049Germany► SubscribePRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
292Luxembourg► SubscribePRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
2015000111Germany► SubscribePRODUCT NAME: OKULARE IRRIGATIONSLOESUNG, WELCHE PHENYLEPHRIN ODER DESSEN PHARMAZEUTISCH WIRKSAMES SALZ UND KETOROLAC ODER DESSEN PHARMAZEUTISCH WIRKSAMES SALZ UMFASST; REGISTRATION NO/DATE: EU/1/15/1018 20150728
C0026France► SubscribePRODUCT NAME: RALTEGRAVIR OU L(UN DE SES SELS PHARMACEUTIQUEMENT ACCCEPTABLES EN PARTICULIER UN SEL DE POTASSIUM; REGISTRATION NO/DATE IN FRANCE: EU/1/07/436/001 DU 20071220; REGISTRATION NO/DATE AT EEC: EU/1/07/436/001 DU 20071220
C/GB10/012United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
C0031Belgium► SubscribePRODUCT NAME: MYCOPHENOLATE MOFETIL; NAT. REGISTRATION NO/DATE: EU/1/96/005/001 19960214; FIRST REGISTRATION: CH 53337 19951103
C0005Belgium► SubscribePRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204
00C/001Belgium► SubscribePRODUCT NAME: DORZOLAMIDI HYDROCHLORIDUM EQ. DORZOLAMIDUM, TIMOLOLI MALEAS EQ. TIMOLOLUM; NAT. REGISTRATION NO/DATE: 922 IS 180 F 13 19981110; FIRST REGISTRATION: DK 19045 19980306
2008006Lithuania► SubscribePRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
00617Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Harvard Business School
Citi
US Army
Colorcon
Mallinckrodt
Baxter
Moodys
Chinese Patent Office
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot